Ads
related to: inspire sleep user reviews consumer reports side effects
Search results
Results From The WOW.Com Content Network
The FDA has labeled a recall of Inspire Medical Systems, Inc.’s (NYSE:INSP) nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire initiated a recall of ...
The implant may be configured to best accommodate the patient's comfort and sleeping habits (e.g., set a delay based on sleep latency). The hypoglossal nerve stimulator implantable pulse generator battery life typically lasts 8–12 years, after which the implantable pulse generator may be safely replaced with another surgery.
Medicare may cover Inspire, a device to treat sleep apnea, if it is medically necessary. A doctor needs to demonstrate that people meet certain criteria and CPAP therapy has been ineffective.
In turn, these conditions of hypoxia and hypercapnia will trigger additional effects on the body such as Cheyne-Stokes Respiration. [17] Some people with sleep apnea are unaware they have the condition. [1] In many cases it is first observed by a family member. [1] An in-lab sleep study overnight is the preferred method for diagnosing sleep ...
Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and is characterized by recurrent episodes of complete or partial obstruction of the upper airway leading to reduced or absent breathing during sleep.
Inspire (INSP) delivered earnings and revenue surprises of 37.70% and 10.90%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?